Table 5.

Clinical Characteristics of the 12 Women Choosing Treatment Options Associated with a 5% or Greater Loss in Predicted Survival

Allocation	Age, y	ER Status	Tumor Size (cm)	Number of Positive Nodes	Tumor Differentiation	Predicted Survival				Treatment Chosen	Loss in Predicted Survivala
						No Adjuvant	Chemotherapy	Hormones	Combined
Control	43	Positive	5	0	Missing	62	74	71	80	Chemotherapy	6
Control	50	Positive	4	5	Moderate	32	36	46	49	Chemotherapy	13
Control	57	Positive	10	13	Moderate	4	10	15	23	Chemotherapy	13
Control	58	Positive	4	0	Poor	60	63	69	71	Chemotherapy	8
Control	62	Positive	3	7	Poor	29	34	42	46	Chemotherapy	12
Control	69	Positive	3	0	Poor	57	58	61	62	No adjuvant	5
Decision aid	43	Positive	3	0	Moderate	76	78	82	83	Chemotherapy	5
Decision aid	51	Positive	10	9	Poor	14	21	15	35	Chemotherapy	14
Decision aid	51	Positive	1	0	Moderate	86	88	89	91	No adjuvant	5
Decision aid	52	Positive	1	1	Moderate	73	77	79	83	Chemotherapy	6
Decision aid	62	Negative	3	0	Poor	70	76	70.5	76	No adjuvant	6
Decision aid	77	Negative	2	1	Moderate	44	49	45	49	No adjuvant	5

^aCalculated by subtracting predicted survival on treatment chosen by the patient from predicted survival had the patient received chemotherapy plus hormonal therapy.